Surgical resection of primary tumor in the extremities improves survival for metastatic soft-tissue sarcoma patients: a population-based study of the SEER database

Matsuoka, Morito; Onodera, Tomohiro; Yokota, Isao; Iwasaki, Koji; Matsubara, Shin; Hishimura, Ryosuke; Kondo, Eiji; Iwasaki, Norimasa

doi:10.1007/s12094-021-02646-1

Cited by 9 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We included STS patients diagnosed from 2010 to 2018, according to the International Classification of Diseases for Oncology (ICD‐O) using the following SEER histology codes: 8800–8806, 8810–8811, 8813–8815, 8821–8822, 8825, 8830, 8832, 8835–8836, 8840–8842, 8850–8855, 8857–8858, 8860, 8890–8891, 8893–8897, 8901–8902, 8910, 8912, 8920–8921, 8983, 8990–8991, 9040–9044, 9120, 9124–9125, 9130, 9133, 9140, 9150, 9170, 9251–9252, 9540, 9560–9561, 9571, and 9580–9581. SEER employs an original histological grading system, so we defined SEER grade 1 as low‐grade tumor, and grade 2–4 as high‐grade tumor 18 . SEER *Stat software (version 8.3.9; National Cancer Institute) was used to obtain the information, and 47260 patients with STSs were identified.…”

Section: Materials and Methodsmentioning

confidence: 99%

“…SEER employs an original histological grading system, so we defined SEER grade 1 as low-grade tumor, and grade 2-4 as high-grade tumor. 18 SEER *Stat software (version 8.3.9; National Cancer Institute) was used to obtain the information, and 47260 patients with STSs were identified. After excluding those patients lacking information about cause of death (292 cases) or primary liver tumor (431 cases), the remaining 46539 patients were included in this study (Figure 1).…”

Section: Patient Populationmentioning

confidence: 99%

See 1 more Smart Citation

Liver metastasis in soft tissue sarcoma at initial presentation

Kawae

Matsuoka

Onodera

et al. 2022

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Noncontrast computed tomography of the chest is the standard imaging modality for cancer staging in patients with soft tissue sarcoma (STS), but appropriate candidates for liver screening have not been clarified. Methods:We reviewed all patients with STS diagnosed between 2010 and 2018 in the Surveillance, Epidemiology, and End Results database. Incidence of liver metastasis at initial presentation and high incidence of liver metastasis by histological subtype were investigated. In addition, risk factors for liver metastasis were investigated by multiple logistic regression analysis.Results: After excluding patients without information about liver metastasis, cause of death or primary liver tumor, 47 260 patients were included in this study. Of those, 1471 patients (3.2%) showed liver metastasis at initial presentation. The histological subtype showing the highest incidence of liver metastasis was desmoplastic small round cell tumor (30.3%), followed by malignant hemangioendothelioma (11.5%) and angiomyoliposarcoma (10.5%). Deep-rooted tumor, location in the body wall, retroperitoneum, or thorax/peritoneum, high histological grade, and higher T stage were associated with higher incidences of liver metastasis at initial presentation. Conclusion:Risk factors for liver metastasis were deep location, trunk development, larger tumor size, high histological grade, and specific histological subtypes.

show abstract

Section: Materials and Methodsmentioning

confidence: 99%

Section: Patient Populationmentioning

confidence: 99%

Liver metastasis in soft tissue sarcoma at initial presentation

Kawae

Matsuoka

Onodera

et al. 2022

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…We did not include infantile fibrosarcoma (8814/3), which represents a clinicopathologically and genetically distinct entity 15 . SEER employs an original histological grading system and we defined SEER grade 1 as low‐grade tumor, and grades 2–4 as high‐grade tumor 12 . The eighth edition of the American Joint Committee on Cancer (AJCC) staging system was used for cancer staging 16 .…”

Section: Methodsmentioning

confidence: 99%

“…Descriptive epidemiological studies using large cancer databases have been reported in the field of rare cancers and are showing new directions in the treatment of patients. 7,[11][12][13][14] We, therefore, hypothesized that the use of large cancer databases could clarify the impact of fibrosarcoma developing in bone on clinical characteristics. The purpose of this study was to investigate the impact of different sites of fibrosarcoma development on clinical features and to clarify risk factors affecting survival in each site.…”

mentioning

confidence: 99%

Comparison of clinical features between patients with bone and soft tissue fibrosarcomas

Matsuoka

Onodera

Yokota

et al. 2022

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Background and Objectives Fibrosarcomas predominantly arise in soft tissues, but can also develop in bone. Because of their rarity, whether bone development has an impact on clinical features has not been addressed. Methods We included fibrosarcoma patients diagnosed between 1983 and 2016 in the Surveillance, Epidemiology, and End Results database. Differences in clinical features between fibrosarcoma of bone (FS‐B) and fibrosarcoma of soft tissue (FS‐ST) were investigated. Results After excluding patients without information regarding cause of death, site of origin, distant tumor or survival, 1443 patients were included. Of those, 98 patients had FS‐B. Patients with FS‐B were younger, more frequently male, with fibrosarcomas that more often developed in an extremity and were histologically high‐grade. In contrast, no difference in potential to metastasize was observed. Survival was almost equal between FS‐B and FS‐ST (FS‐B/FS‐ST: cancer‐specific survival, hazard ratio [HR]: 1.2, 95% confidence interval [CI]: 0.8–1.7; overall survival, HR: 1.3, 95% CI: 0.9–1.7). Conclusions Our results clearly indicated that patient backgrounds differed, such as younger age and greater tendencies to affect males, develop in an extremity and show high‐grade tumor in patients with FS‐B. In contrast, no differences were observed in distant metastatic potential or survival.

show abstract

“…Amputation and lymphadenectomy were performed after evaluation by multidisciplinary team based on the following facts, first, the recurrent tumour presented with high tumour burden in local area, and the tumour mass had ruptured and diabrosis formed over the tumour surface, which resulted in endoprosthesis reconstruction failure. At this condition, amputation would benefit for tumour control and tumour burden reduction; Second, metastatic sarcomas received limb tumour resection are proposed to have better overall survival and improvement of quality of life in short life expectancy (20,21). Following salvage therapy, oral pazopanib (800 mg daily) was administered in February 2020; however, after 30 days of therapy, wound dehiscence occurred.…”

Section: Case Presentationmentioning

confidence: 99%

Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab

et al. 2021

View full text Add to dashboard Cite

Epithelioid sarcoma (ES) is a rare soft tissue sarcoma (STS), with limited therapies available for metastatic disease. Here, we describe a case of a 30-year-old male with ES of the left knee and underwent surgery and radiation therapy for the primary disease. After 2 years, he had local recurrence and underwent extensive resection surgery; however, adjuvant chemotherapies were delayed due to recurrent wound infection. Nine months after the second surgery, progressive disease was confirmed after detection of metastases to the lungs and inguinal lymph nodes. Amputation was performed for the local recurrence, followed by inguinal lymph nodes dissection. Pazopanib was transiently administered but discontinued as a result of wound dehiscence. The tumour specimens were detected with unexpected high level of PD-L1 expression and tumoural infiltrating lymphocytes. Subsequently, he received camrelizumab 2.0 mg/kg every 21 days for 18 cycles with rapid remission of the pulmonary metastases. This promising response to camrelizumab indicates that immunotherapies may be an alternative choice for patients with metastatic ES in lung based on analysing the tumour immune microenvironment.

show abstract

Surgical resection of primary tumor in the extremities improves survival for metastatic soft-tissue sarcoma patients: a population-based study of the SEER database

Cited by 9 publications

References 21 publications

Liver metastasis in soft tissue sarcoma at initial presentation

Liver metastasis in soft tissue sarcoma at initial presentation

Comparison of clinical features between patients with bone and soft tissue fibrosarcomas

Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab

Contact Info

Product

Resources

About